Results 11 to 20 of about 481,852 (106)
A Newfangled Synthesis of Integrase Inhibitor Drug Substance Raltegravir Potassium
Asian Journal of Chemistry, 2019 Raltegravir sodium synthesis was achieved from its one of the key starting materials with retro synthetic approach, in which without using its critical starting material chemically known as 5-methyl-1,3,4-oxadiazole-2-carbonyl chloride and which is more unstable during the synthesis of raltegravir potassium.
S. Venkat Rao +2 more
semanticscholar +4 more sources
Journal of Young Pharmacists, 2019 Objectives: The aim of this present study is to develop an accurate, precise and linear Reverse-phase High-performance Liquid Chromatographic (RPHPLC) method for the estimation of raltegravir potassium in the bulk and pharmaceutical dosage form. Methods: The chromatographic system employs a reverse phase shim-pack C18 column, (150 x 4.6 mm; 5 μ) using ...
Krishna Veni Nagappan +3 more
semanticscholar +4 more sources
Journal of Pharmaceutical Sciences, 2022 Early assessment of pH-dependent drug-drug-interactions (DDIs) for salts of poorly soluble weakly acidic compounds offers various advantages for patient safety, the pharmaceutical industry, and regulatory bodies. Biorelevant media and tests reflecting physiological changes during acid-reducing agent (ARA) co-administration can be used to explore and ...
Andrea Moir +5 more
semanticscholar +4 more sources
Spectrophotometric estimation of raltegravir potassium in tablets.
Indian J Pharm Sci, 2014 Ultra violet spectrophotometric estimation of the raltegravir potassium, an integrase inhibitor antiretroviral agent was estimated by Ultra violet absorption maxima method at λmax of 328 nm and UV area under curve method in the wave length range of 323-333 nm.
Kore PP +3 more
europepmc +5 more sources
Hospital Pharmacy, 2008 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy & Therapeutics Committee. Subscribers also receive monthly 1-page summary monographs on the agents that are useful for agendas and pharmacy/
Dennis J. Cada +2 more
semanticscholar +4 more sources
Antiretroviral drug-drug interactions: A comparison of online drug interaction databases. [PDF]
J Clin Pharm Ther, 2022 Actual or Potential Drug–drug Interactions Identified. Abstract What is known and objective Antiretrovirals have a high drug interaction potential, which can lead to increased toxicity and/or decreased efficacy. Multiple databases are available to assess drug–drug interactions. The aim of our study was to compare interaction identification for commonly
Drwiega EN, Badowski ME, Michienzi S.
europepmc +2 more sources
Acta Médica Portuguesa, 2022 Introduction: Although raltegravir has been available since 2007, data are lacking on the Portuguese population living with HIV who initiated this antiretroviral therapy.
Rosário Serrão +15 more
doaj +1 more source
Journal of Diabetes Investigation, Volume 14, Issue 3, Page 489-493, March 2023., 2023 Human immunodeficiency virus patients receiving antiretroviral therapy can develop immune‐inflammatory reconstitution syndrome. Type 1 diabetes is an autoimmune disease, but type 1 diabetes is rarely reported as immune‐inflammatory reconstitution syndrome.
Maho Taguchi +10 more
wiley +1 more source
Bioinorganic Chemistry and Applications, Volume 2023, Issue 1, 2023., 2023 In this paper, the novel Schiff base ligand containing quinoline moiety and its novel copper chelate complexes were successfully prepared. The catalytic activity of the final complex in the organic reaction such as synthesis of chiral benzimidazoles and anti‐HIV‐1 activity of Schiff base ligand and the products of this reaction were investigated.
Sabikeh G. Azimi +4 more
wiley +1 more source